FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/30/2024
Back to search
Official data from USPTO
UNISTAC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
01/30/2024
Trademark type
Word
Nice classes
5, 42
Filing date
08/06/2021
Registration date
10/10/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/10/2023
Last transaction
10/10/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
KR
Examiner
DYER, ERIN
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
ONEGENE BIOTECHNOLOGY INC.
Representatives
Connie L. Ellerbach Fenwick & West LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the prevention of diseases of the endocrine system; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the prevention of diabetes; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; cardiovascular treatment preparations; pharmaceutical preparations for the prevention of disorders of the nervous system; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the treatment of inflammatory diseases; antibacterial pharmaceuticals; pharmaceutical drugs being pharmaceutical preparations namelyfor the treatment of autoimmune diseasescardiovascular diseases and disorderscentral nervous system diseasesinflammatory diseases and disordersmetabolic diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disorders; synthetic peptides for pharmaceutical purposes namelyfor the treatment of autoimmune diseasescardiovascular diseases and disorderscentral nervous system diseasesinflammatory diseases and disordersmetabolic diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disorders; pharmaceutical compositions for the treatment of autoimmune diseasescardiovascular diseases and disorderscentral nervous system diseasesinflammatory diseases and disordersmetabolic diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disorders; clinical medical reagents; clinical diagnostic reagents for medicinal use; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for use in tissue transplantation; tissue-regenerative pharmaceutical preparations; pharmaceutical preparations for tumor treatment; stimulants for the central nervous system; pharmaceutical preparations for the treatment of central nervous system CNS diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for treating respiratory diseases
Class 42
Research and development of vaccines and medicines; research and development of technology for biotechnology; development of biotechnology; research relating to biotechnology; laboratory research in the field of biology; biological research services; development of new technologies in the field of biologics; drug discovery services; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; research in the field of pharmacogenetics; development of pharmaceutical preparations and medicines; laboratory research in the field of pharmaceuticals; testinginspection and research services in the fields of pharmaceuticalscosmetics and foodstuffs; pharmaceutical drug development services; pharmaceutical research and development; research relating to pharmaceuticals; scientific research in the field of pharmacy; medical laboratory services; research relating to new technologies for medical treatment; medical research laboratory services; scientific research for medical purposes in the area of cancerous diseases; research and development of new technologies for others in the field of amino acid for medical purpose; research and development of new technologies for others in the field of peptide for medical purposes; research and development of technology for medicinal chemical manufacturing; medicine research; scientific research relating to medical substances; medical research; scientific research relating to chemistry
Publications
History of USPTO decisions and trademark events.
36 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/10/2024
FIMP
FINAL DISPOSITION PROCESSED
01/10/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/10/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/10/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
10/10/2023
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
08/31/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/20/2023
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
03/17/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/01/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/01/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/21/2023
PUBO
PUBLISHED FOR OPPOSITION
02/21/2023
GPNX
NOTIFICATION PROCESSED BY IB
02/20/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/01/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/01/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/01/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/18/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/15/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/14/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/14/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/26/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/26/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
10/26/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/26/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/26/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/26/2022
RFNT
REFUSAL PROCESSED BY IB
07/05/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/15/2022
RFRR
REFUSAL PROCESSED BY MPU
06/15/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/13/2022
CNRT
NON-FINAL ACTION WRITTEN
05/12/2022
DOCK
ASSIGNED TO EXAMINER
05/06/2022
MAFR
APPLICATION FILING RECEIPT MAILED
10/09/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/05/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/30/2021
Continuous trademark protection
Get notified about every new filing that threatens UNISTAC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.